{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:55:32Z","timestamp":1793706932198,"version":"4.6.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.autrev.2026.104060","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:50:15Z","timestamp":1776441015000},"page":"104060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives"],"prefix":"10.1016","volume":"25","author":[{"given":"Marion","family":"Larue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bitoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.autrev.2026.104060_bb0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/ni.1900","article-title":"Control systems and decision making for antibody production","volume":"11","author":"Goodnow","year":"2010","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104060_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see and don\u2019t see","volume":"14","author":"Klein","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"HemaSphere"},{"issue":"14","key":"10.1016\/j.autrev.2026.104060_bb0025","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell\u2013depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"issue":"589","key":"10.1016\/j.autrev.2026.104060_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2026.104060_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2002-07-2157","article-title":"Suppression of autoreactive t-cell response to glycoprotein IIb\/IIIa by blockade of CD40\/CD154 interaction: implications for treatment of immune thrombocytopenic purpura","volume":"101","author":"Kuwana","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete b cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun Highlights"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.18582","article-title":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study","volume":"200","author":"Kuwana","year":"2023","journal-title":"Br J Haematol"},{"issue":"36","key":"10.1016\/j.autrev.2026.104060_bb0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"21","author":"Nakayamada","year":"2016","journal-title":"Inflamm Regen"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001424","article-title":"Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report","volume":"12","author":"van Schaik","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104060_bb0075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.43059","article-title":"Safety and efficacy of Ianalumab in patients with Sj\u00f6grens disease: 52-week results from a randomized, placebo-controlled, phase 2b dose-ranging study","volume":"77","author":"D\u00f6rner","year":"2025","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104060_bb0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2414719","article-title":"A Phase 3 trial of Telitacicept for systemic lupus erythematosus","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.autrev.2026.104060_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6grens syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.autrev.2026.104060_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003464","article-title":"Efficacy of daratumumab in refractory primary Sj\u00f6gren disease","volume":"9","author":"Nocturne","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104060_bb0095","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","year":"2023","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.autrev.2026.104060_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu Rev Med"},{"issue":"10416","key":"10.1016\/j.autrev.2026.104060_bb0105","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104060_bb0110","article-title":"CAR t-cell therapy in autoimmune diseases: opportunities and challenges, with implications for RA","volume":"98","author":"Hojati shargh M mahdi","year":"2026","journal-title":"Tissue Cell"},{"issue":"10","key":"10.1016\/j.autrev.2026.104060_bb0115","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104060_bb0120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"0","key":"10.1016\/j.autrev.2026.104060_bb0125","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"0","author":"Gao","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41392-024-01998-8","article-title":"Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future","volume":"9","author":"Mougiakakos","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"14","key":"10.1016\/j.autrev.2026.104060_bb0135","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0145","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"10.1016\/j.autrev.2026.104060_bb0150","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.autrev.2026.104060_bb0155","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104060_bb0160","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.autrev.2026.104060_bb0165","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2026.104060_bb0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through t-cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.autrev.2026.104060_bb0175","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"10.1016\/j.autrev.2026.104060_bb0180","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.autrev.2026.104060_bb0185","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.autrev.2026.104060_bb0190","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104060_bb0195","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.autrev.2026.104060_bb0200","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104060_bb0205","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"1\u201312","author":"Morris","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104060_bb0210","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.autrev.2026.104060_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-06399-1","article-title":"Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"23","author":"Cao","year":"2025","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104060_bb0220","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.autrev.2026.104060_bb0230","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2024-206155","article-title":"Risk of infections in multiple myeloma patients treated with bispecific antibodies","volume":"144","author":"Cani","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0235","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"18","key":"10.1016\/j.autrev.2026.104060_bb0240","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.autrev.2026.104060_bb0250","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1182\/blood-2023-173893","article-title":"The role of intravenous immunoglobulin (IVIG) in reducing infection risk in multiple myeloma (MM) patients receiving immune-based therapies: a single center experience","volume":"142","author":"Lim","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0255","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2026.104060_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.autrev.2026.104060_bb0265","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2026.104060_bb0270","article-title":"1067 ATG-201, a novel \u20182+1\u2019 CD19-targeted T-cell engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases","volume":"12","author":"Bian","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.autrev.2026.104060_bb0275","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.autrev.2026.104060_bb0280","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjh.19960","article-title":"Update on B-cell maturation antigen-directed therapies in AL amyloidosis","volume":"206","author":"Jamroziak","year":"2025","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104060_bb0285","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3324\/haematol.2025.287606","article-title":"Teclistamab for heavily pretreated relapsed\/refractory POEMS syndrome","volume":"111","author":"Talbot","year":"2026","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.autrev.2026.104060_bb0290","first-page":"1891","article-title":"Teclistamab therapy for refractory type 1 cryoglobulinemia","volume":"110","author":"Battaglini","year":"2025","journal-title":"Haematologica"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2026.104060_bb0295","article-title":"A-319, a CD3\u00d7CD19 t cell engager (TCE), for the treatment of severe\/refractory SLE: early evidence of rapid reset of disease-specific autoimmunity","volume":"76","author":"Mei","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104060_bb0300","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ard.2025.06.870","article-title":"ABS0364 safety and efficacy of T cell engager therapy in patients with refractory autoimmune disease","volume":"84","author":"Bucci","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104060_bb0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1515\/rir-2024-0029","article-title":"Therapeutic potential of CD20\/CD3 bispecific antibodies in the treatment of autoimmune diseases","volume":"5","author":"Huang","year":"2025","journal-title":"Rheumatol Immunol Res"},{"issue":"Supplement_1","key":"10.1016\/j.autrev.2026.104060_bb0310","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131650","article-title":"High avidity IgM-based CD20xCD3 bispecific antibody (IGM-2323) for enhanced T-cell dependent killing with minimal cytokine release","volume":"134","author":"Baliga","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0315","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific t cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104060_bb0320","article-title":"A bite of B cells: the potential role of bispecific t cell engager therapy (BiTE) in autoimmune diseases","volume":"28","author":"Zheng","year":"2025","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104060_bb0325","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104060_bb0330","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.autrev.2026.104060_bb0335","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104060_bb0340","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European society for blood and marrow transplantation autoimmune disease working party","volume":"106","author":"Henes","year":"2020","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.autrev.2026.104060_bb0345","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0350","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.autrev.2026.104060_bb0355","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1039\/C9MD00018F","article-title":"Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics","volume":"10","author":"Zorzi","year":"2019","journal-title":"MedChemComm"},{"issue":"8","key":"10.1016\/j.autrev.2026.104060_bb0360","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007398","article-title":"CLN-978, a novel half-life extended CD19\/CD3\/HSA-specific t cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression","author":"Meetze","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.autrev.2026.104060_bb0365","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/19420862.2016.1210747","article-title":"Fab-dsFv: a bispecific antibody format with extended serum half-life through albumin binding","volume":"8","author":"Dav\u00e9","year":"2016","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/abt\/tbad027","article-title":"Next generation of multispecific antibody engineering","volume":"7","author":"Keri","year":"2024","journal-title":"Antibody Ther"},{"issue":"5","key":"10.1016\/j.autrev.2026.104060_bb0375","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1074\/jbc.M116.748707","article-title":"Biological characterization of a stable effector functionless (SEFL) monoclonal antibody scaffold in vitro","volume":"292","author":"Liu","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.autrev.2026.104060_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002488","article-title":"Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"9","author":"Dang","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0390","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s13063-022-06874-w","article-title":"Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial","volume":"23","author":"van Schaik","year":"2022","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.autrev.2026.104060_bb0395","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.3390\/cimb44090261","article-title":"Synthetic TGF-\u03b2 signaling agonist-treated dendritic cells induce Tolerogenicity and antirheumatic effects","volume":"44","author":"Oh","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.autrev.2026.104060_bb0400","article-title":"Sustained codelivery of heat shock protein peptide and rapamycin via nano-in-hydrogel induces immune tolerance in rheumatoid arthritis","volume":"383","year":"2025","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.autrev.2026.104060_bb0405","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpt.2929","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic properties of rozibafusp alfa, a bispecific inhibitor of BAFF and ICOSL: analyses of phase I clinical trials","volume":"114","author":"Abuqayyas","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0410","first-page":"86","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed t cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Can"},{"issue":"1","key":"10.1016\/j.autrev.2026.104060_bb0415","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:36:57Z","timestamp":1780097817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1568997226000741"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104060","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104060"}}